Retrotope is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for degenerative diseases ranging from orphan neurodegenerative indications to large market degenerative conditions. The company leverages its proprietary drug discovery platform to create novel, disease-modifying drugs designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It does so through the creation of isotopically stabilized synthetic versions of polysaturated fatty acids that trigger the down regulation of the LPO process. The company’s lead candidate, RT001, is in clinical development for a range of orphan neurodegenerative diseases including infantile neuroaxonal dystrophy, Friedreich’s ataxia, amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy. In addition, the company is advancing a second candidate, RT011, toward the clinic for the treatment of dry age-related macular degeneration (AMD).
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
RT001 is currently in Phase 2/3 trials for multiple orphan neurodegenerative diseases.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):